Korea's First Blockbuster Obesity Bet Changes the Game

A record that says something about Korea

Hanmi Pharma sold its obesity drug candidate HM17321 to Genentech, a Roche subsidiary, for up to $2.3 billion. The headline number alone — 3.2 trillion won — is the largest single-substance technology export in Korean pharma history. But the number that tells you what is really happening here is far smaller: $190 million.

That is the upfront payment. It represents 8.3 percent of the total deal value, dwarfing the typical 5 percent benchmark for Korean drug exports and more than doubling the $75 million Hanmi itself received just six months ago when it licensed its first GLP-1 candidate, sonelpeglotide, to Eli Lilly. Upfront payments rise when competition intensifies and when buyers believe they are getting something genuinely hard to replicate. Neither condition was accidental.

What makes HM17321 different

The obesity market is now defined by two drugs: Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Both mimic incretin hormones — the same signal your gut sends after eating. They work. They also drain lean muscle along with fat, which lowers metabolic rate and makes weight regain after treatment stop almost inevitable. The industry’s next goal, described openly by every major pharmaceutical company, is to find something beyond incretin drugs.

HM17321 takes a different path entirely. It mimics UCN2, a hormone that drives muscle growth rather than appetite suppression. Hanmi’s research team reprogrammed a molecule previously studied for heart disease into an obesity candidate that preferentially burns fat while preserving and even rebuilding muscle. In clinical terms, that is a first-in-class mechanism — not a variation on existing chemistry, but a new lever pulled in a new direction.

Phase 1 trials began in the United States last November. Genentech is expected to take over Phase 2. The deal gives Genentech exclusive development and commercialization rights everywhere except Korea.

Why Genentech, and why now

Roche has been assembling an obesity portfolio since it acquired Camurus Therapeutics in 2023, picking up the incretin candidate enisoparatide along the way. It also imported petrelintide, an amylin analog, from Zealand Pharma. All three are peptides. HM17321 fits that same molecular family, which means Roche can potentially combine it with its existing candidates rather than starting from scratch. Industry analysts expect exactly that kind of portfolio synergy.

What is less discussed in Western coverage is how aggressively Genentech had to bid. Hanmi’s chief growth officer, Choi In-young, said multiple global pharmaceutical companies entered the race for HM17321 before the deal closed. Choosing Genentech was not an easy call. The 8.3 percent upfront payment is Hanmi’s signal that the buyer placed a high independent valuation on the asset — and that the market sees HM17321 as one of the most coveted late-stage candidates in obesity.

The stock reaction tells the story

Hanmi Pharma’s shares hit the daily limit-up ceiling on the KOSPI, closing at 540,000 won — a gain of nearly 30 percent. Its parent company, Hanmi Science, rose 25.7 percent to 56,500 won. The market did not merely react to a large contract. It reacted to a revaluation.

For years, Korean pharmaceutical companies were valued as manufacturing engines — reliable producers of generics, biosimilars, and some early-stage chemistry. The assumption was that basic innovation belonged elsewhere. HM17321 flips that script. It is a domestically conceived, first-in-class molecule built on original research, licensed to the most expensive buyer in the room. No Korean drug has reached this scale of deal before.

The leadership question

The deal also forces a reassessment of Hanmi’s leadership. After founder Lim Seong-gi died suddenly in 2020, the company spent years in a management dispute that drove away key researchers. The prevailing view in Seoul was that Hanmi’s innovation engine had stalled. Lim Ju-hyun, the founder’s daughter and current vice chair of Hanmi Science, redesigned the company’s obesity and metabolic strategy around a program called H.O.P. HM17321 is the flagship product of that program.

An executive at Hanmi told reporters that professional managers answer to quarterly targets and cannot sustain the long timelines that drug development requires. Lim has worked directly on the Genentech negotiations. Three other candidates from the same pipeline — the GLP-1 drug Effe, launching this October, and the triple-action obesity compound HM15275 — follow the same design philosophy. The question is no longer whether a family-controlled Korean firm can produce global-caliber innovation. It is whether this model can scale.

What happens next

Several things are worth watching closely.

The Phase 2 data for HM17321 will determine whether the muscle-preserving claim holds up at scale. If it does, the drug could reshape the entire category — not just compete with incretin drugs but redefine what an obesity treatment is supposed to do. Muscle preservation matters for older patients, for people who lose weight rapidly, and for anyone concerned about metabolic decline after stopping treatment.

Roche’s next move matters too. If it combines HM17321 with enisoparatide or petrelintide, the resulting regimens could outperform any single-incretin product on the market. That would make the 2023 Camurus acquisition look like a setup, not a bet.

And the broader implication for Korea deserves attention. The last time a Korean pharmaceutical company signed a deal of this magnitude, it was for sonelpeglotide with Eli Lilly — a solid deal, but a second-in-class molecule riding the GLP-1 wave. HM17321 is the opposite: a first-in-class molecule that challenges the wave rather than following it. Seoul is no longer just supplying the world with cheaper versions of Western drugs. It is supplying the world with new ways to think about disease.

The $2.3 billion headline is a milestone. The $190 million upfront payment is the real story.